105 results
SD
SNY
Sanofi
30 May 23
Conflict minerals disclosure
11:15am
-1, the Company excluded packaging materials from this review.
The Company’s global supply chain is complex. In the course of its business operations … in the supply chain between the Company and the original sources of conflict minerals. The Company’s immediate suppliers, in turn, typically are also
SD
SNY
Sanofi
25 May 22
Conflict minerals disclosure
10:10am
, the Company excluded packaging materials from this review.
The Company’s global supply chain is complex. In the course of its business operations … products. Because the Company does not purchase conflict minerals directly from mines, smelters or refiners, there are many third parties in the supply chain between
SD
SNY
Sanofi
21 May 21
Conflict minerals disclosure
3:30pm
and Exchange Commission (“SEC”).
The results of the Company’s RCOI regarding the Subject Minerals are set out below.
The Company’s global supply chain … , smelters or refiners, there are many third parties in the supply chain between the Company and the original sources of conflict minerals. As a result
SD
SNY
Sanofi
22 May 19
Conflict minerals disclosure
6:10am
and Exchange Commission (“SEC”).
The results of the Company’s RCOI regarding the Subject Minerals are set out below.
The Company’s global supply chain … , smelters or refiners, there are many third parties in the supply chain between the Company and the original sources of conflict minerals. As a result
SD
SNY
Sanofi
23 Apr 20
Conflict minerals disclosure
12:37pm
and Exchange Commission (“SEC”).
The results of the Company’s RCOI regarding the Subject Minerals are set out below.
The Company’s global supply chain … , smelters or refiners, there are many third parties in the supply chain between the Company and the original sources of conflict minerals. As a result
SD
i5qv0r 7ppajl7lez5ps
30 May 18
Conflict minerals disclosure
6:36am
6-K
EX-99.4
dkfbl3 2nn8
25 Aug 14
Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
12:00am
6-K
EX-99.2
kjdk0g77eacuw 2jzco
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
k39ufe 5d
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.3
orcgi73
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.2
3r16mpnirmgmsm kb9l5
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
tdsa7nu7041 oh
18 Jun 19
Sanofi and Google to develop new healthcare Innovation Lab
8:44am
6-K
EX-99.1
d64zqc1bugja odjz7xr
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
6-K
EX-99.1
qf5rrb 8buh
15 Oct 19
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology
1:43pm
6-K
EX-99.8
o6oe1273kf6bd
8 Jun 07
Dividend increase of 15.1%; Dividend of €1.75 per share to be paid June 7
12:00am
6-K
EX-99.1
jir2o2ih10ew2w
28 Oct 08
Current report (foreign)
12:00am
6-K
EX-99.2
d03ckq
27 Mar 08
Current report (foreign)
12:00am
6-K
EX-99.4
n9a1fsj1
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
EX-99.3
fpxt9789l6zhgbvrav
30 Jun 21
Sanofi launches dedicated vaccines mRNA Center of Excellence
5:17pm
6-K
EX-99.1
idecr
7 Jul 20
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
12:22pm